Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label PK/PD and Safety Study of Efgartigimod IV in Pediatric Generalized Myasthenia Gravis
2020-005841-18Phase 2Active
- Sponsor
- argenx
- Start
- Jun 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Primary endpoint: Efgartigimod pharmacokinetics (CL and Vd). Started Jun 2021; status: active.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2020-005841-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005841-18.